Funder: National Institutes of Health

Due Dates: September 5, 2025 (New, Renewal, Resubmission, Revision) | January 5, 2026 | April 5, 2026 | September 5, 2026

Funding Amounts: Phase I: up to $700,000 total costs (max $500,000/year, up to 2 years); Phase II: up to $3,000,000 total costs (max $1,500,000/year, up to 3 years); typical awards are lower; see FOA for details.

Summary: Supports U.S. small businesses in conducting exploratory clinical trials for neurological disorder interventions, including drugs, devices, diagnostics, and therapies; SBIR Phase II and Fast-Track only.

Key Information: SBIR Phase I applications are only accepted as part of a Fast-Track; regulatory documentation is required at submission; foreign organizations are not eligible.